Literature DB >> 15232676

Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone.

Landry K Kamdem1, Ingolf Meineke, Ina Koch, Ulrich M Zanger, Jürgen Brockmöller, Leszek Wojnowski.   

Abstract

The polymorphic expression of CYP3A5 in human livers is well established, but its significance for the entire hepatic CYP3A activity is disputed. We investigated the contribution of CYP3A5 to the CYP3A activity assessed as 6beta-hydroxylation of testosterone using baculovirus-expressed CYP3A4 and CYP3A5 and microsomes isolated from 47 Caucasian human livers. Under comparable conditions, the specific activities of baculovirus-expressed CYP3A4 and CYP3A5 were nearly identical. Among human livers tested, the Vmax of 6beta-testosterone hydroxylation varied 28-fold. Of the enzymes that are capable of catalyzing 6beta-hydroxylation of testosterone (CYP3A and CYP1A1), only CYP3A4 mRNA and protein expression correlated significantly with the Vmax values (r=0.51, p<0.001 and r=0.66, p<0.001, respectively). Neither consideration of the CYP3A5 polymorphism nor combining CYP3A4 mRNA expression with the expression of other CYP3A mRNA species increased the correlation. The five livers heterozygous for the CYP3A5*1 allele had a mean 6beta-testosterone hydroxylation Vmax value of 2,976 pmol/mg/min, compared with 3,798 pmol/mg/min in the homozygous CYP3A5*3 livers. Together, these data suggest that the specific activities of CYP3A4 and CYP3A5 towards testosterone are comparable. However, the contribution of CYP3A5 to 6beta-hydroxylation of testosterone in Caucasian livers is limited, due to the much lower expression levels of CYP3A5.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15232676     DOI: 10.1007/s00210-004-0944-3

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  26 in total

1.  Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio.

Authors:  M T Kinirons; Y Krivoruk; G R Wilkinson; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

2.  Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells.

Authors:  B Evert; M Eichelbaum; H Haubruck; U M Zanger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-03       Impact factor: 3.000

3.  The genetic determinants of the CYP3A5 polymorphism.

Authors:  E Hustert; M Haberl; O Burk; R Wolbold; Y Q He; K Klein; A C Nuessler; P Neuhaus; J Klattig; R Eiselt; I Koch; A Zibat; J Brockmöller; J R Halpert; U M Zanger; L Wojnowski
Journal:  Pharmacogenetics       Date:  2001-12

4.  Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities.

Authors:  E M Gillam; Z Guo; Y F Ueng; H Yamazaki; I Cock; P E Reilly; W D Hooper; F P Guengerich
Journal:  Arch Biochem Biophys       Date:  1995-03-10       Impact factor: 4.013

5.  Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe.

Authors:  H Wang; R Dick; H Yin; E Licad-Coles; D L Kroetz; G Szklarz; G Harlow; J R Halpert; M A Correia
Journal:  Biochemistry       Date:  1998-09-08       Impact factor: 3.162

6.  Sex is a major determinant of CYP3A4 expression in human liver.

Authors:  Renzo Wolbold; Kathrin Klein; Oliver Burk; Andreas K Nüssler; Peter Neuhaus; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

7.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

Authors:  J C Gorski; S D Hall; D R Jones; M VandenBranden; S A Wrighton
Journal:  Biochem Pharmacol       Date:  1994-04-29       Impact factor: 5.858

8.  Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.

Authors:  Ina Koch; Regina Weil; Renzo Wolbold; Jürgen Brockmöller; Elisabeth Hustert; Oliver Burk; Andreas Nuessler; Peter Neuhaus; Michel Eichelbaum; Ulrich Zanger; Leszek Wojnowski
Journal:  Drug Metab Dispos       Date:  2002-10       Impact factor: 3.922

9.  Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.

Authors:  Boon-Cher Goh; Soo-Chin Lee; Ling-Zhi Wang; Lu Fan; Jia-Yi Guo; Jatinder Lamba; Erin Schuetz; Robert Lim; Hong-Liang Lim; Ai-Bee Ong; How-Sung Lee
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

10.  Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.

Authors:  Anna Westlind-Johnsson; Sarah Malmebo; Anna Johansson; Charlotta Otter; Tommy B Andersson; Inger Johansson; Robert J Edwards; Alan R Boobis; Magnus Ingelman-Sundberg
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

View more
  2 in total

1.  In vitro cytochrome P450-mediated metabolism of exemestane.

Authors:  Landry K Kamdem; David A Flockhart; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2010-09-28       Impact factor: 3.922

2.  Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?

Authors:  Sven Björkman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.